MGRX vs. MRAI, CCM, BRTX, BGLC, SSY, ACON, ATIP, DHAC, NIVF, and OTRK
Should you be buying Mangoceuticals stock or one of its competitors? The main competitors of Mangoceuticals include Marpai (MRAI), Concord Medical Services (CCM), Biorestorative Therapies (BRTX), BioNexus Gene Lab (BGLC), SunLink Health Systems (SSY), Aclarion (ACON), ATI Physical Therapy (ATIP), Digital Health Acquisition (DHAC), NewGenIvf Group (NIVF), and Ontrak (OTRK). These companies are all part of the "healthcare" industry.
Mangoceuticals vs. Its Competitors
Marpai (NASDAQ:MRAI) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.
Marpai has a beta of 4.66, indicating that its stock price is 366% more volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.42, indicating that its stock price is 142% more volatile than the S&P 500.
49.8% of Marpai shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 46.1% of Marpai shares are held by insiders. Comparatively, 16.0% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Marpai has a net margin of -85.70% compared to Mangoceuticals' net margin of -2,757.86%. Marpai's return on equity of 0.00% beat Mangoceuticals' return on equity.
In the previous week, Mangoceuticals had 1 more articles in the media than Marpai. MarketBeat recorded 2 mentions for Mangoceuticals and 1 mentions for Marpai. Mangoceuticals' average media sentiment score of 1.42 beat Marpai's score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the news media.
Mangoceuticals has lower revenue, but higher earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Marpai beats Mangoceuticals on 7 of the 13 factors compared between the two stocks.
Get Mangoceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mangoceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:MGRX) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access